Drugs that contain Ospemifene
1. Osphena patents expiration
OSPHENA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566252 | DUCHESNAY | Method for the alleviation of dyspareunia in women |
Nov, 2022
(1 year, 5 months ago) | |
| US9241915 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(2 months ago) | |
| US8470890 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(2 months ago) | |
| US8772353 | DUCHESNAY | Method for enhancing the bioavalability of ospemifene |
Feb, 2024
(2 months ago) | |
| US9855224 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(2 months ago) | |
| US6245819 | DUCHESNAY | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
Jul, 2025
(1 year, 2 months from now) | |
| US8236861 | DUCHESNAY | Method for enhancing the bioavailablity of ospemifene |
Aug, 2026
(2 years from now) | |
| US8642079 | DUCHESNAY | Solid formulations of ospemifene |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-793) | Jan 25, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Treatment: Treatment of dyspareunia associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatm...
Dosage: TABLET;ORAL
How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage
OSPHENA family patents
